Is Breast Cancer About To Be Eradicated? Anixa Biosciences' New Vaccine Trials Say May Be

Add as a preferred source on Google

Anixa Biosciences, in partnership with the Cleveland Clinic and backed by a US Department of Defense grant, has made headlines with its Phase 1 breast cancer vaccine-the first in history targeting cancer before it even begins to take root.

This first-of-its-kind immunotherapy, involving three doses over six weeks, trains the body to recognize a protein found in triple-negative breast cancer (TNBC) cells-alpha-lactalbumin-which emerges only during lactation or malignant transformation.

Photo Credit: Freepik

With over 70-75% of participants showing strong immune responses and no serious side effects, researchers are optimistic-and hopeful-that this vaccine could redefine the future of breast cancer prevention.

Novel Approach To Prevent TNBC

This isn't your typical shot-in-the-arm routine. Instead of attacking pathogens, this vaccine trains the immune system to target abnormal expression of a "retired" protein, alpha-lactalbumin, only found again in TNBC cells. By conditioning the body before tumours appear or recur, the therapy creates a preemptive defence-something unprecedented in breast cancer immunology.

What Does Phase 1 Trial Show?

Between 2021 and 2024, researchers enrolled 35 women at high risk, including those who had previously battled TNBC or carried genetic predispositions. The vaccine-administered in three doses two weeks apart-elicited strong immune responses in over 70% of participants, with only mild injection-site irritation reported. Animal studies have further bolstered hope, demonstrating complete prevention of breast tumours in specially bred mice.

Photo Credit: Freepik

What Sets This Vaccine Apart

Cancer vaccines have historically failed due to the immune system's tolerance toward self-cells. But targeting a protein not typically present after lactation makes alpha-lactalbumin a unique, low-risk but highly specific target. That's what excites researchers like Dr. G. Thomas Budd of Cleveland Clinic-who believes this may finally undo some of TNBC's deadliest characteristics.

Phase 2: Block Breast Cancer Before It Starts

The trial's initial success has paved the way for Phase 2, slated to begin in 2025. This next phase aims to assess real-world efficacy-not just safety-including comparisons against standard care, pembrolizumab combinations, and broader demographics. The goal? To prove that this immunization can truly block breast cancer before it starts.

Meanwhile, Anixa and Cleveland Clinic are developing similar vaccines targeting ovarian and other cancers, alongside ongoing work in CAR-T therapy and collaborations like the AI-powered VERDI platform.

Why This Vaccine Is Potentially A Decade-Defining Breakthrough

If effective, this vaccine could shift breast cancer management from treatment to prevention-just like polio vaccines did decades ago . With TNBC affecting 10-15% of breast cancer patients-while accounting for a disproportionate number of fatalities-this could be a remarkable public health milestone .

Perhaps most exciting is the vaccine's promise for genetically predisposed women who choose preventative mastectomy or have completed treatment for early-stage TNBC. Offering them a pharmacological shield against recurrence-or even initial onset-adds a critical safety net rarely available outside surgical intervention.

Anixa's vaccine doesn't just treat breast cancer-it aims to prevent it before cancer ever takes root. With Phase 2 on the horizon, the biotech world watches in hope and skepticism. If trials hold up, we may soon enter an era in which screening and immunization-rather than surgery and chemotherapy-become first-line strategies for high-risk breast cancer patients.

Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.